NCT05193071CompletedPhase 4
Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST)
Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST): a Prospective, Random, Double Blinded and Multi-center Study
Source: ClinicalTrials.gov · Last updated 31 Oct 2024
Brief summary (registry, in English)
The current guideline recommends to give antithrombotic treatment 24 hours after intravenous thrombolysis in acute ischemic stroke. However, early neurological deterioration will occur in some patients due to no antithrombotic treatment, which is closely associated with poor outcome. The current trial aims to investigate the effectiveness and safety of early antithrombotic treatment after intravenous thrombolysis in minor stroke.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 1022 (actual)
- First submitted
- 31 Dec 2021
- Start date
- 8 Jul 2022
- Primary completion date
- 25 Oct 2024
- Lead sponsor
- General Hospital of Shenyang Military Region
- Diseases
- Stroke
- NCT number
- NCT05193071
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 1022
- From 8 Jul 2022 to the primary completion date, 25 Oct 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Significant dysphagia and inability to take the experimental drug orally;
Other illness
- Uncontrolled severe hypertension (systolic pressure \>180 mmHg or diastolic pressure \>110 mmHg after drug treatment);
- Allergy or contraindication to study drugs;
- Comorbidity with any serious diseases and life expectancy is less than half a year;
Other
- Premorbid mRS≥2;
- Antithrombotic treatment within 24 hours before randomization;
- Participating in other clinical trials within three months;
- Patients not suitable for this clinical study considered by researcher
Who the study is looking for
- Age ≥ 18 years old;
- Acute ischemic stroke patients who received intravenous thrombolysis within 4.5 hours of onset;
- NIHSS ≤ 5 within 6 hours after the end of intravenous thrombolysis, and no bleeding transformation was found in head CT examination;
- Premorbid mRS ≤ 1;
- Signed informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hui-Sheng Chen Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
| Department of Neurology, General Hospital of Northern Theater Command Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
Related publications
- Diabetes Mellitus and Early Antiplatelet Treatment for Minor Stroke Following Intravenous Thrombolysis: Prespecified Secondary Analysis of the EAST Trial.Diabetes Obes Metab · 2026 · PMID 41944218
This page is information, not medical advice. Discuss any trial with your doctor.